NCT00437216

Efficacy, Tolerance and Satisfaction With CLOBEX® Spray When Used as Monotherapy or Add-on Therapy in Plaque Psoriasis

Phase 4 Open-Label Multicenter Community-based 4-Wk Trial to Assess Efficacy, Tolerance to Tx & Patient Satisfaction w/ CLOBEX® Spray When Used as Mono- or Add-on Therapy to Existing Systemic/Topical Agents for Tx of Plaque Psoriasis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,488 (actual)
• Sponsor: Galderma R&D · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents.

Detailed description

Evaluation of the effectiveness of Clobex® Spray, 0.05% when used as monotherapy or add-on therapy to existing systemic or topical anti-psoriatic agents, as determined by the change in the target plaque severity (TPS) rating between Weeks 0 and 4.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Clobetasol Propionate, 0.05%	Apply twice daily for 2 or 4 weeks as monotherapy
DRUG	Clobetasol propionate, 0.05% Spray	Apply twice daily for 2 or 4 weeks as add-on therapy

Timeline

• Start date: 2006-02-01
• Primary completion: 2006-07-01
• Completion: 2006-07-01
• First posted: 2007-02-19
• Last updated: 2022-07-29

Locations

1 site across 1 country: United States